John Bisognano
Concepts (305)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of publications
|
Most recent publication
|
Publications by all authors
|
Why?
|
|---|
Hypertension | 31 | 1998 | 161 |
Why?
| Antihypertensive Agents | 21 | 1998 | 54 |
Why?
| Baroreflex | 8 | 2006 | 9 |
Why?
| Electric Stimulation Therapy | 7 | 2006 | 16 |
Why?
| Blood Pressure | 12 | 2004 | 205 |
Why?
| Carotid Sinus | 5 | 2006 | 7 |
Why?
| Drug Resistance | 6 | 2006 | 83 |
Why?
| Diuretics | 4 | 2006 | 18 |
Why?
| Fumarates | 3 | 2008 | 15 |
Why?
| Amides | 3 | 2008 | 28 |
Why?
| Angiotensin-Converting Enzyme Inhibitors | 6 | 1998 | 34 |
Why?
| Humans | 53 | 1993 | 1856 |
Why?
| Renin-Angiotensin System | 3 | 1999 | 15 |
Why?
| Electrocardiography | 5 | 2003 | 132 |
Why?
| Heart Failure | 4 | 1996 | 106 |
Why?
| Electrodes, Implanted | 5 | 2006 | 31 |
Why?
| Amlodipine | 2 | 2004 | 5 |
Why?
| Hospitalization | 2 | 2007 | 169 |
Why?
| Treatment Outcome | 9 | 2004 | 661 |
Why?
| Angiotensin Receptor Antagonists | 2 | 1998 | 7 |
Why?
| Emergency Treatment | 2 | 1999 | 25 |
Why?
| Sympathetic Nervous System | 2 | 2006 | 43 |
Why?
| Renin | 2 | 2008 | 26 |
Why?
| Heart Transplantation | 2 | 1999 | 44 |
Why?
| Heart Neoplasms | 2 | 2008 | 17 |
Why?
| Implantable Neurostimulators | 1 | 2011 | 1 |
Why?
| Sympathectomy | 1 | 2011 | 11 |
Why?
| Adrenergic beta-Antagonists | 2 | 2007 | 47 |
Why?
| Myocardial Ischemia | 2 | 2007 | 62 |
Why?
| Continuous Positive Airway Pressure | 1 | 2010 | 6 |
Why?
| Endocarditis | 1 | 2010 | 12 |
Why?
| Mitral Valve Insufficiency | 1 | 2010 | 19 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 2 | 2008 | 38 |
Why?
| Hypertension, Pregnancy-Induced | 1 | 2009 | 4 |
Why?
| Mitral Valve | 1 | 2010 | 24 |
Why?
| Sleep Apnea, Obstructive | 1 | 2010 | 12 |
Why?
| Female | 20 | 1997 | 1643 |
Why?
| Male | 22 | 1997 | 1553 |
Why?
| Calcium Channel Blockers | 2 | 2007 | 48 |
Why?
| Catheter Ablation | 1 | 2011 | 38 |
Why?
| Hemodynamics | 2 | 2004 | 131 |
Why?
| Pressoreceptors | 1 | 2009 | 10 |
Why?
| Erythema Multiforme | 1 | 2009 | 3 |
Why?
| Metoprolol | 1 | 2009 | 7 |
Why?
| Music | 1 | 2009 | 12 |
Why?
| Retrospective Studies | 8 | 2004 | 653 |
Why?
| Thromboembolism | 1 | 2010 | 27 |
Why?
| Circadian Rhythm | 1 | 2009 | 50 |
Why?
| Staphylococcus aureus | 1 | 2010 | 48 |
Why?
| Pregnancy Outcome | 1 | 2009 | 54 |
Why?
| Diterpenes, Kaurane | 1 | 2008 | 1 |
Why?
| Comorbidity | 3 | 2003 | 190 |
Why?
| Sweetening Agents | 1 | 2008 | 9 |
Why?
| Middle Aged | 15 | 1997 | 1161 |
Why?
| Aged | 13 | 1998 | 988 |
Why?
| Deglutition Disorders | 1 | 2008 | 19 |
Why?
| Heart Diseases | 1 | 2009 | 92 |
Why?
| Echocardiography | 5 | 1998 | 93 |
Why?
| Trans Fatty Acids | 1 | 2007 | 2 |
Why?
| Natriuretic Peptide, Brain | 1 | 2007 | 8 |
Why?
| Blood Urea Nitrogen | 1 | 2007 | 30 |
Why?
| Drugs, Generic | 1 | 2007 | 6 |
Why?
| Cardiac Output, Low | 1 | 2007 | 9 |
Why?
| Energy Intake | 1 | 2007 | 38 |
Why?
| Kidney | 1 | 2011 | 223 |
Why?
| Patient Care Planning | 1 | 2007 | 55 |
Why?
| Protein Precursors | 1 | 2007 | 48 |
Why?
| Vascular Diseases | 1 | 2007 | 60 |
Why?
| Receptors, Endothelin | 1 | 2006 | 15 |
Why?
| Health Policy | 1 | 2007 | 52 |
Why?
| Hospital Costs | 1 | 2006 | 26 |
Why?
| Ailanthus | 1 | 2005 | 1 |
Why?
| Leukoaraiosis | 1 | 2005 | 1 |
Why?
| Geriatric Assessment | 1 | 2007 | 63 |
Why?
| Myocarditis | 1 | 2005 | 10 |
Why?
| Coronary Vasospasm | 1 | 2005 | 7 |
Why?
| Coronary Disease | 2 | 2003 | 94 |
Why?
| Tetrazoles | 1 | 2004 | 9 |
Why?
| Cardiovascular Diseases | 2 | 2004 | 127 |
Why?
| Peptide Fragments | 1 | 2007 | 144 |
Why?
| Valine | 1 | 2004 | 27 |
Why?
| Myocardium | 3 | 1996 | 119 |
Why?
| Brain Ischemia | 1 | 2005 | 45 |
Why?
| Drug Therapy, Combination | 4 | 1998 | 189 |
Why?
| Emergency Service, Hospital | 1 | 2006 | 94 |
Why?
| Stroke | 1 | 2005 | 59 |
Why?
| Acute Disease | 4 | 1999 | 271 |
Why?
| Myocardial Infarction | 2 | 2003 | 129 |
Why?
| Predictive Value of Tests | 3 | 2008 | 321 |
Why?
| Adult | 11 | 1997 | 1317 |
Why?
| Aged, 80 and over | 5 | 1998 | 599 |
Why?
| Receptors, Adrenergic, beta-1 | 1 | 2000 | 2 |
Why?
| Prognosis | 3 | 2007 | 388 |
Why?
| Randomized Controlled Trials as Topic | 3 | 2004 | 176 |
Why?
| Parvovirus B19, Human | 1 | 1999 | 6 |
Why?
| Parvoviridae Infections | 1 | 1999 | 12 |
Why?
| Europe | 2 | 2007 | 54 |
Why?
| Erythropoietin | 1 | 1999 | 21 |
Why?
| Hypertension, Malignant | 1 | 1999 | 6 |
Why?
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2000 | 71 |
Why?
| Animals | 7 | 2000 | 1031 |
Why?
| Stroke Volume | 3 | 2007 | 54 |
Why?
| Immunocompromised Host | 1 | 1999 | 70 |
Why?
| Ventricular Outflow Obstruction | 1 | 1998 | 5 |
Why?
| Heart | 1 | 2000 | 88 |
Why?
| Tricuspid Valve | 1 | 1998 | 16 |
Why?
| Blood Pressure Monitoring, Ambulatory | 2 | 2007 | 9 |
Why?
| Subclavian Artery | 1 | 1997 | 22 |
Why?
| Risk Factors | 3 | 2008 | 555 |
Why?
| Double-Blind Method | 2 | 2008 | 274 |
Why?
| Biological Markers | 3 | 2000 | 262 |
Why?
| Logistic Models | 2 | 2008 | 251 |
Why?
| United States | 3 | 2007 | 604 |
Why?
| Michigan | 2 | 2003 | 13 |
Why?
| Echocardiography, Transesophageal | 2 | 1998 | 33 |
Why?
| Erythrocytes | 2 | 1993 | 109 |
Why?
| Angiotensin II Type 1 Receptor Blockers | 2 | 2004 | 6 |
Why?
| Length of Stay | 2 | 2006 | 166 |
Why?
| Clinical Trials as Topic | 2 | 2007 | 251 |
Why?
| Protons | 2 | 1993 | 30 |
Why?
| Hydroxides | 1 | 1993 | 14 |
Why?
| Labetalol | 2 | 1999 | 3 |
Why?
| Feasibility Studies | 2 | 2004 | 144 |
Why?
| Emergencies | 2 | 1999 | 57 |
Why?
| Ventricular Function, Left | 1 | 2011 | 41 |
Why?
| Severity of Illness Index | 2 | 1999 | 358 |
Why?
| Nafcillin | 1 | 2010 | 2 |
Why?
| Rhinitis, Allergic, Perennial | 1 | 2010 | 5 |
Why?
| Practice Guidelines as Topic | 2 | 2010 | 174 |
Why?
| Echocardiography, Doppler, Color | 1 | 2010 | 8 |
Why?
| Retinal Vessels | 1 | 2010 | 17 |
Why?
| Maternal Mortality | 1 | 2009 | 6 |
Why?
| Eclampsia | 1 | 2009 | 8 |
Why?
| Blood Pressure Determination | 1 | 2009 | 19 |
Why?
| Meta-Analysis as Topic | 1 | 2010 | 30 |
Why?
| Carotid Body | 1 | 2009 | 7 |
Why?
| Follow-Up Studies | 2 | 2003 | 553 |
Why?
| Pre-Eclampsia | 1 | 2009 | 18 |
Why?
| Time Factors | 2 | 2007 | 896 |
Why?
| Hypersensitivity | 1 | 2010 | 39 |
Why?
| Diastole | 1 | 2009 | 21 |
Why?
| Markov Chains | 1 | 2009 | 25 |
Why?
| Systole | 1 | 2009 | 31 |
Why?
| Heart Atria | 1 | 2009 | 37 |
Why?
| Prenatal Care | 1 | 2009 | 35 |
Why?
| Monitoring, Physiologic | 1 | 2009 | 81 |
Why?
| Takotsubo Cardiomyopathy | 1 | 2009 | 3 |
Why?
| Creativeness | 1 | 2009 | 5 |
Why?
| Hydroxyzine | 1 | 2009 | 4 |
Why?
| Adrenal Cortex Neoplasms | 1 | 2009 | 10 |
Why?
| Histamine H1 Antagonists | 1 | 2009 | 13 |
Why?
| Periodicity | 1 | 2009 | 28 |
Why?
| Hypotension | 1 | 2009 | 33 |
Why?
| Pheochromocytoma | 1 | 2009 | 21 |
Why?
| Coronary Angiography | 2 | 2005 | 49 |
Why?
| Treatment Failure | 1 | 2009 | 88 |
Why?
| Drug Evaluation, Preclinical | 1 | 2008 | 65 |
Why?
| Chi-Square Distribution | 1 | 2009 | 179 |
Why?
| Equipment Design | 1 | 2009 | 132 |
Why?
| Proportional Hazards Models | 1 | 2009 | 123 |
Why?
| Posture | 1 | 2008 | 68 |
Why?
| Kidney Diseases | 1 | 2010 | 90 |
Why?
| Carotid Arteries | 1 | 2009 | 51 |
Why?
| Placebos | 1 | 2008 | 110 |
Why?
| Health Status Indicators | 1 | 2008 | 66 |
Why?
| Esophageal Neoplasms | 1 | 2009 | 37 |
Why?
| Diet, Sodium-Restricted | 1 | 2007 | 13 |
Why?
| Diet, Fat-Restricted | 1 | 2007 | 5 |
Why?
| Minoxidil | 1 | 2007 | 3 |
Why?
| Drug Costs | 1 | 2007 | 22 |
Why?
| Hospitals, Special | 1 | 2007 | 8 |
Why?
| Chlorthalidone | 1 | 2007 | 3 |
Why?
| Sodium Chloride Symporter Inhibitors | 1 | 2007 | 4 |
Why?
| Evidence-Based Medicine | 1 | 2009 | 125 |
Why?
| Body Weight | 1 | 2008 | 178 |
Why?
| Combined Modality Therapy | 1 | 2009 | 219 |
Why?
| Electric Stimulation | 1 | 2007 | 101 |
Why?
| Patient Readmission | 1 | 2007 | 23 |
Why?
| Video Games | 1 | 2007 | 10 |
Why?
| Risk Reduction Behavior | 1 | 2007 | 26 |
Why?
| Ambulatory Care Facilities | 1 | 2007 | 27 |
Why?
| Creatinine | 1 | 2007 | 69 |
Why?
| Diet | 1 | 2008 | 87 |
Why?
| Exercise | 1 | 2008 | 82 |
Why?
| Receptors, Cell Surface | 1 | 2008 | 115 |
Why?
| Diabetes Complications | 1 | 2007 | 49 |
Why?
| Patient Admission | 1 | 2007 | 72 |
Why?
| Risk | 1 | 2007 | 203 |
Why?
| Captopril | 1 | 2006 | 13 |
Why?
| Multivariate Analysis | 1 | 2008 | 225 |
Why?
| Forecasting | 1 | 2007 | 147 |
Why?
| Clonidine | 1 | 2006 | 24 |
Why?
| Metabolic Syndrome X | 1 | 2007 | 34 |
Why?
| Obesity | 1 | 2010 | 149 |
Why?
| Vasoconstriction | 1 | 2006 | 37 |
Why?
| Asthma | 1 | 2010 | 97 |
Why?
| Patient-Centered Care | 1 | 2007 | 30 |
Why?
| Heart Rate | 1 | 2008 | 138 |
Why?
| Treatment Refusal | 1 | 2006 | 31 |
Why?
| Young Adult | 1 | 2009 | 380 |
Why?
| Patient Compliance | 1 | 2007 | 113 |
Why?
| Anti-Bacterial Agents | 1 | 2010 | 195 |
Why?
| Nerve Fibers, Myelinated | 1 | 2005 | 18 |
Why?
| Nitroglycerin | 1 | 2005 | 10 |
Why?
| Magnetic Resonance Imaging | 2 | 2008 | 294 |
Why?
| Risk Assessment | 1 | 2009 | 324 |
Why?
| Disease Models, Animal | 1 | 2009 | 349 |
Why?
| Isoproterenol | 1 | 2004 | 47 |
Why?
| Vasodilator Agents | 1 | 2005 | 56 |
Why?
| Adrenergic beta-Agonists | 1 | 2004 | 39 |
Why?
| Survival Rate | 1 | 2007 | 250 |
Why?
| Prevalence | 1 | 2007 | 281 |
Why?
| 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid | 2 | 1993 | 9 |
Why?
| Dementia | 1 | 2005 | 56 |
Why?
| Emergency Medical Services | 1 | 2006 | 61 |
Why?
| Graft Rejection | 1 | 2005 | 59 |
Why?
| Fatal Outcome | 2 | 1997 | 86 |
Why?
| Pregnancy | 1 | 2009 | 455 |
Why?
| Transplantation, Homologous | 1 | 2005 | 94 |
Why?
| Energy Metabolism | 1 | 2004 | 80 |
Why?
| Troponin I | 1 | 2003 | 6 |
Why?
| Chlorides | 2 | 1993 | 69 |
Why?
| Cardiovascular Agents | 1 | 2003 | 18 |
Why?
| Patient Education as Topic | 1 | 2005 | 128 |
Why?
| Creatine Kinase | 1 | 2003 | 37 |
Why?
| Cerebral Cortex | 1 | 2005 | 108 |
Why?
| Syndrome | 1 | 2003 | 142 |
Why?
| Sex Distribution | 1 | 2003 | 101 |
Why?
| Disease Progression | 1 | 2005 | 244 |
Why?
| Age Distribution | 1 | 2003 | 127 |
Why?
| Genetic Predisposition to Disease | 1 | 2005 | 131 |
Why?
| New York | 1 | 2007 | 422 |
Why?
| Odds Ratio | 1 | 2003 | 157 |
Why?
| Reference Values | 1 | 2003 | 278 |
Why?
| Regression Analysis | 1 | 2003 | 256 |
Why?
| Diagnosis, Differential | 2 | 1997 | 402 |
Why?
| Rats | 1 | 2009 | 530 |
Why?
| bcl-2-Associated X Protein | 1 | 2000 | 40 |
Why?
| Fenoldopam | 1 | 1999 | 1 |
Why?
| Nitroprusside | 1 | 1999 | 24 |
Why?
| Drug Monitoring | 1 | 1999 | 33 |
Why?
| Injections, Intravenous | 1 | 1999 | 105 |
Why?
| Infusions, Intravenous | 1 | 1999 | 87 |
Why?
| Adolescent | 1 | 2008 | 891 |
Why?
| Aortitis | 1 | 1997 | 1 |
Why?
| Dyspnea | 1 | 1997 | 13 |
Why?
| Aneurysm, Infected | 1 | 1997 | 10 |
Why?
| Cough | 1 | 1997 | 20 |
Why?
| Aortic Aneurysm, Thoracic | 1 | 1997 | 12 |
Why?
| Proto-Oncogene Proteins | 1 | 2000 | 113 |
Why?
| Mice, Transgenic | 1 | 2000 | 209 |
Why?
| Brain | 1 | 2005 | 305 |
Why?
| Heterogeneous-Nuclear Ribonucleoprotein D | 1 | 1996 | 3 |
Why?
| Streptococcus pyogenes | 1 | 1997 | 26 |
Why?
| Gene Expression | 1 | 2000 | 291 |
Why?
| Receptors, Adrenergic, beta | 1 | 1996 | 35 |
Why?
| Potassium | 2 | 1993 | 98 |
Why?
| Sodium | 2 | 1993 | 96 |
Why?
| Membrane Potentials | 2 | 1993 | 99 |
Why?
| Streptococcal Infections | 1 | 1997 | 54 |
Why?
| Chronic Disease | 1 | 1997 | 267 |
Why?
| Gramicidin | 1 | 1994 | 3 |
Why?
| Valinomycin | 1 | 1994 | 8 |
Why?
| Postoperative Complications | 1 | 1999 | 305 |
Why?
| RNA-Binding Proteins | 1 | 1996 | 55 |
Why?
| Ethoxzolamide | 1 | 1993 | 1 |
Why?
| 4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid | 1 | 1993 | 8 |
Why?
| Carbocyanines | 1 | 1993 | 13 |
Why?
| Apoptosis | 1 | 2000 | 265 |
Why?
| Body Water | 1 | 1993 | 25 |
Why?
| Saline Solution, Hypertonic | 1 | 1993 | 12 |
Why?
| Benzothiazoles | 1 | 1993 | 22 |
Why?
| Osmolar Concentration | 1 | 1993 | 91 |
Why?
| Indicators and Reagents | 1 | 1993 | 79 |
Why?
| Scattering, Radiation | 1 | 1993 | 36 |
Why?
| Hemoglobins | 1 | 1993 | 74 |
Why?
| Sucrose | 1 | 1993 | 35 |
Why?
| Light | 1 | 1993 | 64 |
Why?
| Sleep Apnea Syndromes | 1 | 2010 | 15 |
Why?
| Gene Expression Regulation | 1 | 1996 | 277 |
Why?
| Hypertension, Pulmonary | 1 | 2010 | 22 |
Why?
| Endoscopy, Gastrointestinal | 1 | 2009 | 17 |
Why?
| Esophagogastric Junction | 1 | 2009 | 10 |
Why?
| Quality-Adjusted Life Years | 1 | 2009 | 22 |
Why?
| Sex Characteristics | 1 | 2010 | 85 |
Why?
| Catecholamines | 1 | 2009 | 40 |
Why?
| Cost-Benefit Analysis | 1 | 2009 | 118 |
Why?
| Mice | 1 | 2000 | 623 |
Why?
| RNA, Messenger | 1 | 1996 | 394 |
Why?
| Cohort Studies | 1 | 2009 | 332 |
Why?
| Sensitivity and Specificity | 1 | 2009 | 427 |
Why?
| Tomography, X-Ray Computed | 1 | 2009 | 321 |
Why?
| Oxygen Consumption | 1 | 2004 | 86 |
Why?
| Polyribosomes | 1 | 1996 | 15 |
Why?
| Muscle, Smooth | 1 | 1996 | 69 |
Why?
| GTP-Binding Proteins | 1 | 1996 | 47 |
Why?
| Intracellular Fluid | 1 | 1994 | 38 |
Why?
| Ion Transport | 1 | 1994 | 42 |
Why?
| Ultraviolet Rays | 1 | 1996 | 76 |
Why?
| Cell Membrane Permeability | 1 | 1994 | 57 |
Why?
| DNA Primers | 1 | 1996 | 208 |
Why?
| Recombinant Proteins | 1 | 1996 | 290 |
Why?
| Base Sequence | 1 | 1996 | 371 |
Why?
| Molecular Sequence Data | 1 | 1996 | 404 |
Why?
| Signal Transduction | 1 | 1996 | 313 |
Why?
|
|
Bisognano's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
